When evaluating AOD-9604, one of the most contentious debates centers on administration: oral tablets vs. subcutaneous injections. While oral administration sounds far more appealing than a daily needle prick, the biological and clinical reality tells a different story.

If systemic bio-availability and predictability are the primary goals, subcutaneous injection is overwhelmingly considered superior.

The Bio-availability Hurdle: Why Oral Peptides Struggle

Peptides are chains of amino acids, and your gastrointestinal tract treats them just like protein from food.

When you ingest AOD-9604 orally, it encounters a gauntlet of gastric acid, digestive enzymes (pepsin, trypsin, chymotrypsin), and first-pass hepatic metabolism. Because peptides are hydrophilic and relatively large, very little survives enzymatic breakdown to cross the intestinal wall into systemic circulation intact.

• Estimated oral bio-availability: Typically under 1% to 3% for unformulated oral peptides.
• The commercial fallout: Metabolic Pharmaceuticals originally pursued an oral tablet formulation. Their landmark Phase IIb clinical trial, which enrolled over 500 patients on oral doses, failed to show statistically significant weight loss over a placebo. Many researchers largely attributed this failure to erratic absorption and poor oral bioavailability.

Subcutaneous Injection: Direct Systemic Delivery

Subcutaneous (SubQ) administration bypasses the entire digestive tract by delivering the peptide directly into the fatty layer beneath the skin.

• Near-complete systemic uptake: By avoiding stomach acid and hepatic first-pass metabolism, SubQ delivery yields far higher plasma concentrations and a more predictable absorption curve.
• Peak concentration: SubQ injections typically achieve peak plasma levels within 30 to 60 minutes.
• Targeted utilization: Because intact molecules enter the capillary bed directly, adipocytes receive higher exposure to active AOD-9604 before endogenous proteases degrade it.

Direct Comparison: Oral vs. Subcutaneous

Metric	Subcutaneous Injection	Oral (Capsules / Tablets)
Bio-availability	High and consistent	Very low; subject to digestion
Dosing Predictability	Reliable plasma absorption	Highly variable across individuals
Convenience	Requires needles, reconstitution, and cold storage	Non-invasive swallowable pill
Clinical Trial Precedent	Supported in animal & tissue studies	Failed primary endpoints in human Phase IIb
Risk Profile	Mild injection-site redness/bruising	Gastrointestinal upset, minimal systemic effect

Why Are Oral Versions Still Sold?

If oral delivery is so inefficient, why do oral capsules and sublingual troches flood online research sites?

1. Market demand for non-invasive products: The barrier to entry for self-injection is high; casual consumers prefer pills.
2. Regulatory gray areas: Supplement and research vendors often market oral versions under loose dietary-ingredient premises to sidestep compounding scrutiny.
3. Sublingual alternatives: Some vendors compound troches or drops designed to absorb through mucosal membranes under the tongue, but published human pharmacokinetic aka ADME trials demonstrating systemic efficacy for AOD-9604 troches remain virtually nonexistent.

So which is better in the end of the two types of intake?

From a strictly pharmacological perspective, subcutaneous injection is the better, more effective route.

Oral ingestion exposes the fragile 16-amino-acid chain to enzymatic destruction before it can stimulate fat oxidation in target tissues. Unless paired with proprietary permeation enhancers or advanced protective nanocarriers, oral AOD-9604 yields negligible systemic exposure. For researchers seeking measurable, predictable physiological effects, subcutaneous delivery remains the standard protocol.